ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0238

Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Abstract Number: 0239

Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
Abstract Number: 0240

Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
Abstract Number: 0241

Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Abstract Number: 0242

Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
Abstract Number: 0243

Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Abstract Number: 0244

Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Abstract Number: 0245

Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study
Abstract Number: 0246

Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
Abstract Number: 0247

Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Abstract Number: 0248

Clinical and serological characteristics of anti-Ku autoantibodies in a Hispanic cohort
Abstract Number: 0249

Obesity as a possible confusion factor in the scleroderma pattern
Abstract Number: 0250

Autoinflammatory diseases in adult patients. Spanish registry.
Abstract Number: 0251

Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
Abstract Number: 0252

Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].